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Abstract
Background: The Health-sector Wide (HsW) priority setting model is designed to shift the focus
of priority setting away from 'program budgets' – that are typically defined by modality or disease-
stage – and towards well-defined target populations with a particular disease/health problem.
Methods: The key features of the HsW model are i) a disease/health problem framework, ii) a
sequential approach to covering the entire health sector, iii) comprehensiveness of scope in
identifying intervention options and iv) the use of objective evidence. The HsW model redefines
the unit of analysis over which priorities are set to include all mutually exclusive and
complementary interventions for the prevention and treatment of each disease/health problem
under consideration. The HsW model is therefore incompatible with the fragmented approach to
priority setting across multiple program budgets that currently characterises allocation in many
health systems. The HsW model employs standard cost-utility analyses and decision-rules with the
aim of maximising QALYs contingent upon the global budget constraint for the set of diseases/
health problems under consideration. It is recognised that the objective function may include non-
health arguments that would imply a departure from simple QALY maximisation and that political
constraints frequently limit degrees of freedom. In addressing these broader considerations, the
HsW model can be modified to maximise value-weighted QALYs contingent upon the global budget
constraint and any political constraints bearing upon allocation decisions.
Results: The HsW model has been applied in several contexts, recently to osteoarthritis, that has
demonstrated both its practical application and its capacity to derive clear evidenced-based policy
recommendations.
Conclusion:  Comparisons with other approaches to priority setting, such as Programme
Budgeting and Marginal Analysis (PBMA) and modality-based cost-effectiveness comparisons, as
typified by Australia's Pharmaceutical Benefits Advisory Committee process for the listing of
pharmaceuticals for government funding, demonstrate the value added by the HsW model notably
in its greater likelihood of contributing to allocative efficiency.
Background
The primary task of priority setting is to determine desira-
ble resource shifts – health services to be expanded and
those to be contracted – to support the achievement of
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health and other social objectives. A number of priority
setting models have been employed by third-party fund-
holders to this end including Program Budgeting and
Marginal Analysis (PBMA) and various approximations to
the QALY league table approach. A number of recent
reviews describing key features of existing priority setting
models and their application are available for those unfa-
miliar with the literature [1-5].
While these models have the capacity to identify desirable
resource shifts, the challenges of funding and delivery
under a global budget have led to a fragmentation of the
health sector into 'program budgets' or 'budgetary silos' –
typically defined by modality or disease-stage. One conse-
quence of this fragmentation into program budgets is that
allocation and re-allocation of resources commonly
occurs within, rather than between, budgetary silos. Where
mutually exclusive interventions are funded under differ-
ent program budgets, decision-makers may consider only
options within their ambit, failing to identify more cost-
effective options outside their program area. Competing
interventions funded under different budgets may also be
required to clear different hurdles, such that funding may
be easier to obtain for cure than for prevention, for drug-
therapy than for counselling, or for inpatient care than for
treatment in a community setting. Unless any such differ-
ences in the probability of funding can be linked to some
argument in the objective function that systematically var-
ies by program budget, then efficiency gains are available
by shifting resources between budgetary silos. Further,
complementarities between modalities in the treatment
of a particular disease/health problem may be ignored,
such that composite interventions or coordinated
approaches to prevention or treatment must rely on ad
hoc funding unless their component parts can be shown
to be independently cost-effective.
In short, an emphasis on priority setting at the level of
program budgets, defined by modality or disease-stage
may entrench allocative inefficiency – particularly
between budgetary silos.
In this paper we describe an economic model that explic-
itly considers resource allocation across modality (medi-
cal, surgical, pharmaceutical, media, allied health etc.)
and disease-stage (primary prevention, early diagnosis,
management of established disease and end stage care/
palliation). It is argued that this focus on allocation and
re-allocation of resources across the care continuum and
across modalities for each disease/health problem under
consideration has the capacity to deliver allocative effi-
ciency gains when compared to priority setting models
that are predominantly concerned with the narrower
question of allocation within a program budget. It is
argued that, because of the disease/ health problem focus
and the involvement of a broad range of interests – the
model is also less likely to promote capture by a single
interest group.
Methods
The model
The Health-sector Wide (HsW) priority setting model is
designed to shift the focus of priority setting away from
'program budgets' that are typically defined by modality
or disease-stage and towards well-defined target popula-
tions with a particular disease/health problem. The key
features of the model are a disease/health problem frame-
work, a sequential approach to covering the entire health
sector, comprehensiveness of scope in identifying inter-
vention options and reliance on objective evidence, but
with a limited role for clinical experts and consumers.
Since publication of an early version in 1994 [6], the HsW
model has been refined and applied in several disease-
areas. The current paper describes the refined model, dis-
cusses issues arising from application of the model that
bear upon implementation, and compares the model to
other economic models of priority setting.
The model categorises the entire health sector into dis-
eases and health problems. The point of adopting this cat-
egorisation, which undoubtedly is a simplification, is to
provide a framework that allows the health sector wide
priority setting task to be staged. In essence, fragmenta-
tion of the health sector by 'program budgets' that are typ-
ically defined by modality, disease-stage or agency, is
replaced by classification by disease/health problem
which in large part equates with particular sub-popula-
tions. This approach supports a staged analysis as that the
likelihood of sub-optimising is reduced by a process that
requires a wide range of competing interventions to be
considered in a single priority setting exercise. The logic of
a priority setting approach that seeks to identify how most
efficiently to reduce burden on sub-populations of dis-
ease/health conditions/risk factors derives from the object
of health care, which is the health of populations, not the
provision of health care as an end in itself. In contrast,
analysing interventions within a specific delivery context
– such as modality or agency – in effect presumes there are
no substitutes outside that context. If that is not the case,
the priority setting process will inevitably result in sub-
optimising. That is while it may support an efficient distri-
bution of funding within the nominated context (eg phar-
maceuticals), it will almost certainly be inefficient in
funding that context relative to others.
After imposing the disease/health problem categorisation,
the model hypothesises that the disease burden can
potentially be addressed by intervening through: i) pri-
mary prevention targeted at persons at risk, ii) early diag-
nosis (and treatment) of persons with undiagnosedCost Effectiveness and Resource Allocation 2006, 4:6 http://www.resource-allocation.com/content/4/1/6
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diseases, iii) management of persons with established dis-
ease and iv) palliation for persons in the terminal phase.
This categorisation is purposefully comprehensive, but
recognises that for certain diseases there may be no feasi-
ble intervention at one or more disease stage.
This continuum of care within a specific disease/health
problem defines the unit of analysis over which priorities
are set, with the aim of including all mutually exclusive
and complementary interventions for the prevention and
treatment of that disease/health problem. That is to say,
priority setting exercises initially proceed within the rele-
vant disease/health problem column in Table 1 below,
but is to eventually encompass the entire health sector via
sequential or parallel application across columns.
Once a disease or health problem area has been selected,
the model involves 10 distinct tasks to be completed by
decision-makers and analysts, some of which proceed
together rather than sequentially:
1. Obtain a thorough understanding of the disease/health prob-
lem – in terms of disease aetiology, normal disease pro-
gression and feasible points of intervention to reduce
disease burden.
2. Set up an Expert Panel of clinicians and consumers to
assist with access to, and interpretation of the clinical and
health economics literature and for later dissemination of
findings.
3. Identify all intervention options at each disease stage – pro-
ceeding cell by cell, down a column. Comprehensiveness
in terms of modality, health delivery setting, target popu-
lation, philosophy of care, occupation group/professional
mix and method of delivery is paramount. The aim is to
include all mutually exclusive and complementary inter-
ventions for the prevention and treatment of the disease/
health problem under consideration. Interventions iden-
tified by horizon scanning should be included, as well as
existing technologies, without regard, in the first instance
to the quality of available evidence.
4. Select interventions to include in the priority setting exercise
– From all possible interventions identified, select inter-
ventions for estimation and comparison of performance.
The selection should aim for comprehensiveness, contin-
gent upon constraints related to the availability of evi-
dence. Any intervention that is currently funded or is
likely to receive funding should be included. Where lack
of evidence precludes formal evaluation, the identified
data gaps should feed into research priorities – see also
discussion under 7.
5. Specify the measure of benefit – The selected measure of
benefit should allow comparison within and between col-
umns in Table 1 above and reflect community values.
Consider whether defined benefit should extend beyond
the individual (to include impact on family members/the
wider community) and whether health maximisation
should be the sole concern. The QALY or value-weighted
Table 1: HsW (Health-sector wide) model framework
Disease stage 
Target population
Disease or health problem Total budget 
allocated to 
disease stage
Musculoskeletal CVD Cancers Endocrine Etc ........
OA RA CHD stroke Lung, Breast, CRC IDDM NIDDM
Primary 
prevention Persons 
at risk
Early diagnosis 
Persons 
undiagnosed
Management 
Persons with 
established disease
Palliative care 
Persons in terminal 
phase
Total budget 
allocated to 
prevention and 
management
Notes: OA osteoarthritis, RA Rheumatoid arthritis, CVD cardio-vascular disease, CHD coronary heart disease, CRC colorectal cancer, IDDM 
insulin dependent diabetes mellitus (Type 1), NIDDM non-insulin dependent diabetes mellitus (Type 2).Cost Effectiveness and Resource Allocation 2006, 4:6 http://www.resource-allocation.com/content/4/1/6
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QALY – incorporating mortality, quality of life and other
dimensions of benefit (such as equity) – are perhaps the
most suitable composite outcome measures that support
comparisons across disparate interventions.
6. Collect evidence on costs and outcomes primarily from the
published clinical trial literature. Identify all published
studies that provide evidence on outcomes and costs
(resource use) for the interventions to be included in per-
formance measurement. Locate and use studies of 'best'
quality, with respect to study design, sample size, length
of follow-up and reporting of pertinent interpretable out-
comes, and the precision with which intervention and
comparator are specified.
7. Identify critical data gaps in the primary clinical trial evi-
dence and to estimate downstream and broader 'external'
impacts. Use this information to inform research priori-
ties. In the short-term, scenario analysis, informed by
expert opinion may be used to estimate performance, rec-
ognising however, that where evidence is poor, estimated
performance may be too imprecise to develop recommen-
dations concerning desirable resource shifts.
8. Calculate the cost-effectiveness of each intervention at each
disease stage – that is within each cell of Table 1, working
down the relevant disease/health problem column. Use
standard techniques of cost-effectiveness analysis [7,8]
with an emphasis on achieving comparability in perform-
ance measurement. This inevitably means intermediate
outcomes must be translated into final outcomes and
modelling beyond published trial results.
9. Compare the performance of interventions within and across
disease stages – within cell comparisons can potentially
proceed using intermediate outcomes but between cell
comparisons require a 'final' composite outcome measure
such as the QALY or value-weighted QALY.
10. Develop conclusions about desirable resource shifts – iden-
tify desirable resource shifts based on the relative perform-
ance of competing and complementary interventions and
sort these resource shifts by the level of supporting evi-
dence. Interventions excluded from the performance
measurement task due to a lack of evidence but still of
interest (for instance because they are currently funded),
should be listed alongside interventions for which per-
formance measurement was possible.
Implementation/Results
A number of challenges arise when applying the simple
HsW model described above. First, a lack of objective evi-
dence on effectiveness for the full range of intervention
options (existing and potential) across settings, sub-pop-
ulations and the care continuum may leave a potentially
large number of interventions excluded from explicit per-
formance measurement. Secondly, converting clinical and
other outcomes into a common unit of benefit to support
comparison of interventions across disease stages and
across diseases is problematic due to data gaps and unre-
solved methodological questions. Thirdly, decision-mak-
ers frequently prefer to leave political, ethical or
distributional objectives implicit rather than support
explicit decision-rules based on objective evidence.
The extent to which these challenges impede implementa-
tion of the HsW model has been explored in applications
to osteoarthritis [9], Type 2 Diabetes [10,11], hyperten-
sion and harmful life style behaviours [12,13]. These
applications have shown that the HsW model is not dis-
tinguished from other priority setting models by its ability
to overcome these problems. Rather, it is the sort of ques-
tions that the HsW model emphasises that distinguishes it
from priority setting models that are predominantly con-
cerned with the narrower question of allocation within a
program budget. The disease/health problem framework
of the HsW model supports explicit consideration of allo-
cation and reallocation of funding across all mutually
exclusive and complementary interventions for the pre-
vention and treatment of a disease/health problem under
consideration. The published applications demonstrate
the robustness of the framework in this task and in devel-
oping recommended resource shifts across disparate
modalities and across disease stages, which, if followed,
should contribute to social objectives and that application
across the entire health sector is feasible. (Recommenda-
tions have covered for instance, exercise, patient educa-
tion, surgery, complementary medicines, prescription
medicines, public health campaigns, primary care advice
etc.).
That said, the translation of recommendations to actual
resource shifts is dependent on the incentives in the
health system and in particular whether funding arrange-
ments are compatible with the health sector wide context
and disease/health problem framework. The most com-
patible funding framework is a global budget for the (sub)
population, managed by a single fundholder. The align-
ment of budgetary silos with the disease/health problem
framework might also be successful. A mismatch between
the funding framework and the priority setting framework
requires a mechanism for shifting resources between
budgets. This could plausibly be achieved by permitting
one fundholder to 'buy-out' the budget of another fund-
holder provided suitable accountability mechanisms are
in place. More generally, the very funding models that
give rise to the observed distortions in the health service
mix discourages any redirection of resources to address
them. Whilst the HsW model is not distinguished from
other priority setting models by its ability to overcomeCost Effectiveness and Resource Allocation 2006, 4:6 http://www.resource-allocation.com/content/4/1/6
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this problem, it does identify the cost of retaining funding
silos. Setting priorities at the level of the program budget
will typically fail to identify this major source of ineffi-
ciency.
In relation to consideration of interventions for which the
evidence is extremely poor, the solution in the medium to
longer term has to lie in the gathering of additional evi-
dence. The alternatives are to adopt the status quo – to
continue to fund unproven interventions, which in effect
means adding to but not deleting interventions from the
formulary (requiring an ever expanding program budget),
or rely on the black-box of committee or working-group
decision-making, allowing decision-maker values or
expert opinion to determine the final list of priorities. Nei-
ther alternative is likely to promote efficiency. In the short
term, a lack of data should not be allowed to paralyze the
decision-making process. The HsW model avoids decision
paralysis by retaining all competing and complementary
interventions of interest in the choice set but differentiat-
ing interventions according to the level of supporting evi-
dence. The extent of reliance on opinion and the sway of
political imperatives in modifying the set of priorities is
therefore made quite explicit when implementing the
HsW model. The value of the HsW model is to identify
data gaps, highlight the need for objective evidence and
avoid any confusion between opinion-base and evidence-
based decision-making.
Comparison with other priority setting models
The HsW model has elements in common with other eco-
nomic-based approaches such as QALY League Tables
[2,14], PBMA [1,15-17] and generalised cost-effectiveness
analysis [18,19]. A full description and critique of all com-
peting priority setting models is beyond the scope of the
current paper but the key features of three alternative eco-
nomic models, together with a brief consideration of their
strengths and weakness relative to the HsW model, are
outlined below. See also the critique by Coast and col-
leagues [2], the report by Segal and Chen [3] and the dis-
cussion paper by Hauck and colleagues [4].
Limited/constrained comparisons
Typically in health economic evaluation a small number
of interventions are compared, often drawing on the
results of a single clinical trial or a meta-analysis of similar
trials. The process for the listing of pharmaceuticals on
government formularies, such as the Australian Pharma-
ceutical Benefits Schedule (PBS) is a well-known example
of a restricted approach to priority setting. In order for
drugs to be listed on the PBS (a mechanism to subsidise
pharmaceuticals) pharmaceutical companies must sub-
mit an economic evaluation to support listing. Evalua-
tions are prepared according to a set of published
guidelines [8] and submissions are subject to independent
review. Other treatment modalities are ineligible for list-
ing.
The process ensures consistency in methods and high
standard of analysis. But the guidelines define the main
comparator narrowly, as another drug, normally of the
same pharmacological analogue – if such a drug is listed
on the PBS, or otherwise of the same therapeutic class.
Comparison with 'standard medical management' occurs
only on the rare occasion when there is no suitable com-
parator listed on the PBS. This restriction on scope means
that drug treatment is rarely compared with alternative
modalities and never with modalities that do not repre-
sent usual care. In the context of an open ended pharma-
ceutical budget (where supply responds without limit to
demand, as applies in Australia), this process supports the
increasing use of pharmaceuticals relative to other modal-
ities. This will be the result unless the performance thresh-
old, in terms of incremental cost-effectiveness ratio, that
supports listing is set to reflect decision making elsewhere
in the health sector. But it is more likely that decisions on
pharmaceuticals will be made independently, without
regard to the incremental cost-effectiveness ratios of com-
peting modalities that could be obtained through a
broader health sector wide approach to priority setting. In
the absence of that broader context, limited cost-effective-
ness comparisons are at clear risk of entrenching resource
silos within program boundaries and modalities.
QALY league tables
QALY league tables in contrast attempt to be comprehen-
sive, with the aim of comparing all current and possible
health interventions in a single priority setting exercise.
The most commonly cited example of QALY League
Tables in action is the Oregon Experiment of the early
1990s – an attempt to identify a set of health services to be
funded under the US Medicaid program for the people of
Oregon [14]. The research program and subsequent rec-
ommendations ran into difficulties, due to lack of confi-
dence in the cost and QALY estimates, but also a
fundamental mistrust of the allocation of resources on the
basis of cost/QALY. The difficulty posed by the sheer
scope of the exercise is substantial, especially if the analy-
sis is to be truly at the margin and to consider all possible
target populations and intervention options [21].
Of the four alternative economic models considered here,
QALY league tables share the greatest commonality with
the HsW model. It is therefore worth highlighting exactly
how the HsW model addresses some of the difficulties
experienced when using QALY league tables for priority
setting. The HsW model addresses issues related to the
lack of confidence in cost/QALY estimates by permitting
the measure of benefit to capture ethical or distributional
concerns, by a reliance on objective evidence with respectCost Effectiveness and Resource Allocation 2006, 4:6 http://www.resource-allocation.com/content/4/1/6
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to all arguments in the objective function for interven-
tions included in performance measurement tasks, and by
making explicit the lack of evidence associated with inter-
ventions excluded from the performance measurement
but included in the priority setting exercise. The HsW
model addresses the vastness in scope and size of task, by
dividing the priority setting exercise into a succession of
manageable research activities, covering all mutually
exclusive and complementary interventions for the pre-
vention and treatment of a single disease/health problem.
That is, by adopting the disease/health problem frame-
work described above.
Generalised Cost-Effectiveness (G-CE) analysis
was developed to resolve issues with regards the transfer-
ability and policy applicability of cost-effectiveness analy-
sis (CEA) that might limit or preclude its use and re-use
for sector-wide priority setting [18,19]. More specifically,
Murray and colleagues [19] provide a set of guidelines for
G-CEA with two potential situations in mind: (i) "CEA of
a wide-range of interventions ...to inform a specific deci-
sion-maker facing a known budget constraint, a set of
options for using the budget and a series of other (ethical
or political) constraints" (p237), and (ii) "CEA of a wide-
range of interventions ...to provide general information
on the relative costs and health benefits of different tech-
nologies that are meant to contribute through multiple
channels to a more informed debate on resource alloca-
tion priorities" (p237). Given the alignment of budgetary
silos with the disease/health problem framework or the
existence of a global budget managed by a single fund-
holder for the (sub) population under study, the applica-
tion of the HsW model would be equivalent to the first
situation. However, in the presence of a mismatch
between the funding framework and the priority setting
framework, the HsW model would have more in common
with the second situation – informing debate by identify-
ing the cost of retaining budgetary silos and a narrow
focus on resource shifts within a program budget. In either
case, addressing the issues raised in the development of G-
CEA might also be considered a pre-requisite for the use
and re-use of the HsW model.
Several of these issues have been discussed above includ-
ing: the availability of a suitable composite outcome
measure that can support comparisons across disparate
interventions and identifying political constraints on the
set of possible resource shifts. However, the pivotal issue
raised in development of the G-CEA model is the limited
transferability of cost-effectiveness ratios in the presence
of a complex series of dependencies between the costs and
effects of related interventions. If cost-effectiveness is cal-
culated relative to a comparator that is available in one
population but not in another, then the resulting cost-
effectiveness ratio will be applicable and policy-relevant
in only one of those populations. In principle, evaluating
sets of related interventions with respect to the 'null set' of
related interventions (rather than with respect to the cur-
rent mix of available interventions) would yield cost-
effectiveness ratios that are independent of any such
dependencies between related interventions.
After evaluating related interventions with respect to the
null set of related interventions, the G-CEA model
requires that independent sets of mutually exclusive inter-
ventions be ordered in increasing order of cost per unit of
outcome, before applying standard decision rules for con-
strained maximisation. The G-CEA model can therefore
be viewed as an adaptation of the QALY League Table
approach, designed to enhance the transferability of
results from one population to another. The G-CEA
model de-contextualises CEA analyses, eschewing con-
text-specific distributional concerns and taking only lim-
ited account of political constraints such that enhanced
transferability may come at the price of policy-relevance.
Decision-makers attempting to derive a context-specific
set of priorities would then have to perform the usual
adjustments to the price and quantity of inputs and to the
coverage, efficacy and adherence of interventions [18], as
well as conducting multiple indirect comparisons (when
the null set is not politically feasible in the relevant con-
text and to recover incremental comparisons against cur-
rent practice) and re-weighting outcomes to reflect
context-specific distributional concerns [22,23].
Program Budgeting and Marginal Analysis (PBMA)
is a relatively common approach to priority setting in the
health sector, developed in the context of health agency
decision making. The key features are; i) the establish-
ment of a Working Group (from the health organisation
and possibly other constituencies) to determine program
objectives and to identify a set of services to be expanded
and another set to be contracted, based on consideration
of possible benefits (gained or lost) from service expan-
sion or contraction, ii) estimation of budgets for sub-pro-
grams, and iii) calculation of cost-effectiveness ratios for
each intervention in the expansion and contraction lists
(optional).
The strength of this approach derives from the engage-
ment of the key players in the task through the primary
role of the Working Group, arguably increasing the likeli-
hood that recommendations will be implemented. It is
also possible to complete such an exercise at relatively low
cost and with few data inputs. The key limitation of PBMA
relates to the subjectivity of the process and consequent
lack of confidence in the rankings and specifically in the
expansion and contraction set identified. Peacock and col-
leagues [21], for example, report only a weak relationship
between recommended Panel rankings and cost-effective-Cost Effectiveness and Resource Allocation 2006, 4:6 http://www.resource-allocation.com/content/4/1/6
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ness estimates prepared by the research team (even when
measuring effectiveness to reflect objectives developed by
the Panel). While it is possible that cost-effectiveness
ratios do not adequately capture the range of social objec-
tives that influencing rankings, it is also possible that
rankings that rely heavily on subjective assessments will
fail to reflect arguments in the social welfare function and
will instead reflect decision-maker values. The latter is a
particular concern given that the process has few require-
ments around the quality of the evidence-base and may be
vulnerable to capture by vested interest.
Partly to address the limitations of a traditional PBMA
analysis, Carter and colleagues have emphasised the
importance of incorporating objective evidence into pri-
ority setting, whilst maintaining a core role for the Work-
ing Group. This work has progressed under the acronym
of ACE: Assessment of Cost-Effectiveness (24, 25). Under
ACE the incremental cost per DALY is adopted as the pri-
mary measure of performance, but 'second stage filters'
such as 'acceptability', 'implementability', budget impact
and equity are considered through a subjective process,
possibly changing recommendations. The Working
Group selects the intervention options and assists in the
application of the 'second stage filters'. The research team
prepares the cost/DALY estimates based on the clinical
trial literature supported by economic and epidemiologi-
cal modelling.
The ACE model has much in common with the HsW
model, notably the disease focus and the greater reliance
on objective evidence. Where it differs from the HsW
model is in the role of the Working Group in selecting
intervention options, rather than the use of objective cri-
teria for this purpose, the adoption of the DALY as the pri-
mary measure of outcome, and the role for 'second stage
filters' in the ranking of interventions to account for distri-
butional concerns and to bring selected implementation
issues into the priority setting exercise. While the ACE
model does not allow the primary measure of outcome to
be adjusted to account for non-health dimensions of ben-
efit, the use of second-stage filters allows for other issues,
including barriers to implementation that might modify
the list of priorities to be made explicit. The selection of
interventions by the Working Group remains as a source
of inefficiency.
To date, the majority of PBMA exercises have set priorities
at the level of relatively narrow program budgets that
rarely include all mutually exclusive and complementary
interventions for the relevant (sub) population [26].
Recently, the term macro marginal analysis (MMA) has
been coined to describe the application of PBMA methods
across disease-stages, disease-areas, modalities and pro-
gram budgets administered by major integrated health
care organisations [27]. The rationale for the development
of MMA PBMA is much the same as for the development
of the HsW model – to eliminate artificial constraints that
entrench allocative inefficiency. However, the choice set is
delimited firstly, by the ambit of the budget-holder (a
constraint not present in the HsW model) and secondly,
by the expansion and contraction lists compiled by the
Working Group. It is worth noting that reluctance among
program managers to nominate interventions for contrac-
tion has been identified as a key challenge in the imple-
mentation of MMA. Mitton and colleagues [27] argue that
a recent implementation of MMA to identify desirable
resource shifts for one regional health authority (Alberta,
Canada) confirms that it is possible for a PBMA working
group to pragmatically compare re-allocation options at
the level of a regional health authority and achieve
resource release of a significant magnitude without formal
measurement of health benefits and without attaching
explicit weights to competing objectives. While a compar-
ison of re-allocation options without measurement and
without a well-defined objective function is certainly pos-
sible, the more pertinent question would seem to be
whether or not the resulting trade-offs are likely to leave
people better-off or worse-off? The fact that resource shifts
are acceptable to the Working Group provides little in the
way of reassurance.
Discussion
The primary strengths of the HsW model are: i) the health
sector wide framework, ii) a means to stage the priority
setting task to encompass all health interventions, that
minimising the risk of sub-optimising, iii) the require-
ment for comprehensiveness in the range of interventions
options – which reduces the influence of the status quo or
vested interest on the scope of the priority setting exercise
and ensures that priorities are set over all mutually exclu-
sive and complementary interventions for the prevention
or treatment of the disease/health problem under consid-
eration; iv) the requirement for objective evidence; v) the
separation of the technical priority setting task from
implementation. The adoption of a disease focus has
many advantages, including efficiency in the research
activity, reduction in the number of target groups for
interventions and a commonsense understanding of the
recommendations.
Whilst the requirement for comprehensiveness in scope
presents a specific challenge of the HsW model, our expe-
rience in applying the HsW model in a number of disease-
areas has suggested a number of strategies in delimiting
the set of interventions for formal performance measure-
ment, whilst still meeting this requirement:
• Within a disease-area, interventions can be sorted into
'types' and evaluated as, for example, 'self-managementCost Effectiveness and Resource Allocation 2006, 4:6 http://www.resource-allocation.com/content/4/1/6
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interventions for type II diabetes' or 'brief GP interven-
tions for problem drinking'. While it is true that there may
be differences in the intensity and approach of specific
interventions within each type, types can be defined so as
to be homogeneous with respect to key characteristics
such as program logic and this approach is more palatable
than the PBMA approach to delimiting the choice set (ie,
working group nominates expansion and contraction
lists).
• Retaining all competing and complementary interven-
tions of interest in the choice set but excluding interven-
tions with insufficient evidence to support formal
evaluation from the performance measurement task.
• Frequently 'simple modelling' will identify those inter-
ventions that can be considered highly cost-effective and
those at the other end of the spectrum. Resources can then
be reserved for detailed modelling of those interventions
that fall somewhere in the middle.
Given such strategies, our experience suggests that appli-
cation of the HsW model, within a single disease, will
involve perhaps 25 cost-utility analyses and can be com-
pleted for around 5 person years of research: that is, for
~A$500,000 (or ~US$370,000). This would typically rep-
resent <0.05% of the resources allocated to management
and prevention of the disease in question. Application of
the HsW model typically results in clear recommenda-
tions for resource shifts between health services, across
modalities and across disease stages. The highly disparate
estimates of cost/QALY between interventions, means
that the potential for health gain from recommended
resource shifts is substantial. With opportunities identi-
fied to shift resources from interventions costing
>$100,000/QALY gain to others costing <$10,000 per
QALY gain, yielding potentially nine extra QALYs at no
additional cost. Desirable resource shifts identified from
application of the HsW model to osteoarthritis, Type 2
Diabetes, hypertension and harmful life style behaviours
are specified elsewhere [9,11,12].
The loss in social benefit if recommendations are not fol-
lowed can be calculated, as can the implied value (or cost)
of non-health objectives and of political constraints.
Keeping the priority setting exercise separate from issues
of implementation is particularly important in this
respect, supporting the development of clear recommen-
dations based on the health care objectives identified in
the priority setting exercise rather than political consider-
ations. Priority setting models which attempt to identify
and implement desirable resource shifts tasks in the one
exercise; whilst possibly increasing the likelihood of
implementation in the short term, may lose clarity with
regards to objectives and decision criteria.
Key challenges in application remain. These challenges
are not unique to the HsW model, but intrinsic to any
attempt to compare performance across disparate inter-
ventions. Of the available alternative models, an evi-
dence-based PBMA of the sort described in the ACE
studies carries many of the advantages of the HsW model.
However, one of the strengths of PBMA – its responsive-
ness to local objectives and constraints – may also leave
the process open to capture by vested interest. That said,
lessons learnt from the application and refinement of
PBMA and the HsW model suggest that a comprehensive
approach to priority setting across the care continuum
and across modalities is likely to provide a shorter route
to optimal allocation of health resources than the sort of
revision at the margin or narrow program focus that char-
acterises common approaches to priority setting.
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